tbuckley/cabot-search huggingface dataset:
Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)
Authors: V. Westeel, F. Barlesi, P. Foucher, J.-J. Lafitte, J. Domas, P. Girard, J. Tredaniel, M. Wislez, P. Dumont, E. Quoix, O. Raffy, D. Braun, M. Derollez, F. Goupil, J. Hermann, E. Devin, E. Pichon, J.-P. Gury, F. Morin, P.-J. Souquet
Journal: Annals of Oncology (2017)
Pharmacokinetics and safety of FOLFOX therapy in patients undergoing hemodialysis
Authors: Shigeki Kataoka, Toshihiko Kirishima, Taro Funakoshi, Takahiro Horimatsu, Shina Sueki, Yohei Harada, Masami Nakajima, Shunsaku Nakagawa, Motoko Yanagita, Manabu Muto
Journal: Annals of Oncology (2017)
Survival by sidedness of metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor antibodies (EGFR-Ab) in the refractory setting: A population-based study of 1509 patients
Authors: E. Segelov, C. Earle, A.P. Venook, R. Saskin, L. Mofid, S. Singh
Journal: Annals of Oncology (2017)
Bidirectional chemotherapy in gastric cancer (GC) with peritoneal carcinomatosis (PC) combining intravenous chemotherapy with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: An open-label, phase II study.
Authors: Vladimir Khomiakov, Andrey Ryabov, Larisa V Bolotina, Anna Utkina, Vadim Cheremisov, Ilya Kolobaev, Andrey Ivanov, Anna Chayka, Dmitry Sobolev
Journal: Journal of Clinical Oncology (2017)

e15532 Background: Up to 40% of GC patients show synchronous PC at time of diagnosis and peritoneal relapse develops in 10–46% of cases after radical surgery. Systemic chemotherapy is standard method of treatment with median survival of several months. Innovative therapeutic approaches are needed to improve survival. Methods:Phase-2, open label prospective clinical trial assessing safety and efficacy of bidirectional chemotherapy for treating of gastric cancer with PC. Treatment protocol for untreated patients included initial staging laparoscopy or laparotomy, 3–4 courses of systemic chemotherapy (XELOX) followed by Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) procedures every 6 weeks until progression of disease or death. Criteria of progression included 50% and more PCI increase or distant metastases. Patients with primary or recurrent GC, who received earlier one or two lines of systemic chemotherapy, didn’t receive 4 XELOX courses before PIPAC. Primary endpoints were overall survival and histological peritoneal regression grading score after rebiopsy. Results:46 patients were included (14 men, 32 women, mean age 53.5 years), 33 patients had primary GC with PM and 13 had peritoneal relapse after surgery. 15 patients had systemic chemotherapy before inclusion to the program. About one half of patients had ascites. Mean PCI was 12.1 (min-max 3-34). Altogether, 89 PIPAC procedures were performed in the 46 patients. Complete and partial pathological response was found in 91% of the 23 patients eligible for tumor response assessment (7 and 14 patients, respectively). Median survival was 14 months and one-year overall survival was 55%. The median survival was better in patients with low PCI in compare with high PCI, but the difference was not significant. Conclusions: Bidirectional chemotherapy combining XELOX with PIPAC with cisplatin and doxorubicin can induce objective tumor regression and is associated with a promising survival in GC with PC.
Eight-year follow up results of the OTOASOR trial: The optimal treatment of the axilla – surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. A randomized, single centre, phase III, non-inferiority trial
Authors: Á. Sávolt, G. Peley, C. Polgár, B. Győrffy, Z. Mátrai
Journal: Annals of Oncology (2017)
Predictive and prognostic value of tumor cells and circulating plasma free DNA in advanced epithelial ovarian carcinoma
Authors: J. Martinez-Garcia, A. Minguela Puras, P.A. Cascales Campos, M.V. Martinez Sanchez, J. Gil Martinez, F. Barcelo Valcarcel, J.R. Rodriguez Hernandez, M.A. Torroba Caron, A. Soto-Gutierrez, P. Sanchez Henarejos, A. Puertes Boix, S. Montenegro Luis, P. Ruiz Carreño, E. Rodriguez Braun, M.D. Jimenez Lucas, M. Guirao Marín, M.A. Cuellar Rivas, A. Cano Jimenez, A. Anton Garcia, J.L. Alonso Romero
Journal: Annals of Oncology (2017)
RetroSpective cohort stUdy of PD-L1 expression in REcurrent and/or MEtastatic squamous cell carcinoma of the head and neck (SUPREME-HN)
Authors: S. Pai, E.E. Cohen, D. Lin, G. Fountzilas, E.S. Kim, H. Mehlhorn, N. Baste, D. Clayburgh, L. Lipworth, C. Resteghini, N. Shara, T. Fujii, J. Zhang, M. Stokes, D. Lawrence, A. Khaliq, G. Melillo, N. Shire
Journal: Annals of Oncology (2017)
Abstract 17690: Statin Use Protects Against Systemic Inflammation in a Geriatric Population: The Brazilian Study on Healthy Aging
Authors: Sameer Shaharyar, Omar Jamal, Ehimen C Aneni, Wladimir M Freitas, Luiz A Quaglia, Rafaela C de Paula, Raul D Santos, Michael J Blaha, Seth S Martin, Roger S Blumenthal, Arthur S Agatston, Andrei C Sposito, Khurram Nasir
Journal: Circulation (2013)

BACKGROUND: Clinical trial data has demonstrated that statins reduce vascular inflammation. However, data describing the association between statin use and markers of vascular inflammation such as ...
An 11-Year-Old Boy With Vision Loss
Authors: Dustin Jacobson, Kamiar Mireskandari, Eyal Cohen
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Evaluation of various prognostic scores and impact of cell of origin on survival in limited stage DLBCL: retrospective study
Authors: M.S. Rauf, S. Akhtar, T. Ahmed, M. Elhassan, Q. Shaikh, F.A. Almugbel, M.N. Zahir, N. Bakshi, I. Maghfoor
Journal: Annals of Oncology (2017)
Epidemia persistente de hepatitis A en la región de Pulla (Italia), 1996: estudio epidemiológico
Authors: P L Lopalco, P Malfait, S Salmaso, C A Germinario, M Quarto, S Barbuti, R Cipriani, A Mundo, G Pesole
Journal: Eurosurveillance (1997)

A comienzos del ano 1996, se observo un incremento de los casos declarados de hepatitis A en la region de Pulla, en el sudeste de Italia. En mayo de 1996 se llevo a cabo un estudio epidemiologico que mostro una fuerte asociacion entre la enfermedad y el consumo de mariscos crudos (odds ratio (OR) = 31,8 [12,1-118]); asociandose tambien el aumento de riesgo de infeccion, al almacenamiento de los mariscos en agua marina en el lugar de venta (1). A pesar de los consejos que se impartieron sobre el manipulado y consumo de los mariscos, aumento el numero de casos en la region de la Pulla durante los meses siguientes, encontrandose un pico en agosto de 1996 en la provincia de Bari. Por ello, se comenzo un nuevo estudio de investigacion para identificar todos aquellos factores de riesgo que pudieran ser responsables de la persistencia de esta epidemia.
Gastric cancer detected after Helicobacter pylori eradication at one private screening center in Japan
Authors: T. Nakamura, Y. Kon, K. Konuma, T. Sanada, S. Shibata, H. Gonda, Y. Suto, Y. Amagasa, A. Suzuki, M. Fukuda, C. Aoyagi
Journal: Annals of Oncology (2017)
Camouflaging iRGD-EGFR anchored human cytotoxic T-lymphocyte membranes to the surface of nanoparticles combined with low-dose irradiation: New approach to enhance drug-delivery targeting in gastric cancer
Authors: L. Zhang, H. Sha, R. Li, J. Wei, X. Qian, B. Liu
Journal: Annals of Oncology (2017)
Biomarker testing practices in the SECURE (proSpective obsErvational clinical practiCe stUdy in the first-line management of metastatic colorectal cancer [mCRC] with eRbitux in combination with chemothErapy) study
Authors: G. Aravantinos, A. Shahrasbi, M. Oukkal, B. Larbaoui, P. Ronga, D. Messinger, J. Hamad, W. Benbrahim
Journal: Annals of Oncology (2017)
ESEN : comparación de programas de vacunación - Primera parte: difteria
Authors: D Lévy-Bruhl, R G Pebody, I Veldhuijzen, M Valenciano, K Osborne
Journal: Eurosurveillance (1998)

El objetivo de la Red Europea de Vigilancia Serologica (European Sero-Epidemiology Network, ESEN) es coordinar y armonizar la vigilancia serologica de la inmunidad a las enfermedades prevenibles por vacunacion en ocho paises de Europa (Dinamarca, Inglaterra, Francia, Alemania, Italia, los Paises Bajos, Finlandia y Suecia). Se establecio en marzo de 1996 en el marco del programa Biomed II de la Comunidad Europea y esta coordinada por el Centro de Vigilancia de Enfermedades Transmisibles de Londres (Public Health Laboratory Service Communicable Disease Surveillance Centre, CDSC).
Experience with the implant of vascular access devices by medical oncologist in a non-surgical scenery
Authors: A. Revuelta, D. Rodríguez Rubí, M.L. Sánchez Lorenzo, L. Ruiz Echeverria, W. Li, M.P. Solís Hernández, L. Fáez García, S. Fernández Arrojo, C. Iglesias Gómez, N. Villanueva Palicio, P. Jimenez Fonseca, M. Luque Cabal, C. Álvarez Fernández, M. Izquierdo, J.M. Viéitez, E. Esteban
Journal: Annals of Oncology (2017)
Tumor microenvironment in high serous ovary cancer: Characterization of the infiltration pattern and analysis of its prognostic value
Authors: F. Herrera Cañizares, A. Chipirliu, C. Caballero, A. Herreros Pomares, S. Calabuig Fariñas, L. Valdivieso, M. Mosqueda, J. Marí Alexandre, E. Jantus Lewintre, J. Gilabert, C. Camps Herrero
Journal: Annals of Oncology (2017)
PTU-062 Investment in a dedicated biosimilar ibd nurse and pharmacist facilitates provision of a high quality infliximab infusion service and reduces infusion-related costs
Authors: S Cotton, S Garnish, M Brown, R Saich, J Gordon, D Lloyd
Journal: Gut (2017)

Introduction  We instituted a biosimilar switch programme in September 2015 in adult IBD patients. Predicted cost savings were used to recruit a dedicated IBD nurse and pharmacist who supervised the switch and reviewed and updated pathways for administration of biologicals. Their appointments allowed completion of point of care assessments, standardised monitoring of drug levels and facilitated a switch from on site vial reconstitution of infliximab to pre-ordering of pre-filled bags.  The aim of this study was to assess the impact of the IBD nurse and pharmacist on patient management, patient satisfaction and pharmacy costs.  Method  Data were reviewed over a 16 month period from the start of the biosimilar switch programme to the end of December 2016. As part of the programme, enhanced monitoring of patients including completion of disease activity scores (HBAI and SCCAI) and Patient Recorded Outcome (PRO) was performed at each infusion. Data were contemporaneously recorded. Patients were asked to complete a satisfaction questionnaire 6 months after they switched to biosimilar infliximab. Pharmacy records were interrogated and cost savings estimated using standard NHS salary and procurement costs.  Results  Over the review period 235 patients received infliximab. A total of 1182 HBAI and SCCAI assessments and 1115 PROs were completed and infliximab levels and dosing were monitored prior to each infusion. 74/235 (31%) of patients had their treatment altered as a direct result of these assessments with 60 patients having their infliximab dose or dose interval altered and 14 patients switching to an alternative biological.  71 patients completed the satisfaction questionnaire. All were pleased (11%) or very pleased (89%) with their overall standard of care. Patients thought that their standard of management was the same (60%), better (20%) or much better (20%). They reported that their disease activity was the same (68%), better (26%) or much better (6%).  Estimated cost savings from switching from on site vial reconstitution of infliximab to ordering pre-filled bags totalled £4280 over the review period as a result of staff time saved and reduced consumable costs. Additional review of pharmacy records identified incorrect drug charging with a subsequent refund of £12 000 to the Trust.  Conclusion  Integration of a dedicated IBD nurse and pharmacist into the infliximab infusion service as part of a switch to biosimilar infliximab has helped achieve a responsive service with excellent patient satisfaction measures. It also achieved cost savings over and above those expected from the switch from originator to biosimilar infliximab.  Disclosure of Interest  None Declared
Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levels
Authors: M. Schuler, L. Nogova, A. Heidenreich, D. Tai, P. Cassier, H. Richly, B.C. Cho, C.M. Sayehli, A. Navarro, S. Bender, M. Ocker, H. Nogai, A. Wagner, S. Ince, P. Ellinghaus, M. Joerger
Journal: Annals of Oncology (2017)
GW28-e1151 The analysis of complications on radiofrequency catheter ablation of arrhythmias in Chinese military hospitals
Authors: Guitang Yang, Wang Zulu, Jin Zhiqing, Liang Ming, Liang Yanchun, Sun Mingyu, Zhang Ping, Ding Jian, Han Yaling, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
Reply
Authors: Christian von Loeffelholz, Andreas L. Birkenfeld
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. Reply: Chen et al. propose a further loop to the IL‐6/STAT3–mIndy axis1 by recalling that interleukin‐6 (IL‐6) is an important player in chronic inflammation–related hepatocellular carcinoma (HCC). Moreover, excellent work in human hepatoma cell lines showed that RNAi‐mediated knockdown of the citrate transporter mINDY was associated with a decrease in cell proliferation, colony formation, and expression of cyclin B1. Metabolically, intracellular levels of citrate, the ATP/ADP ratio, phospholipid content, ATP citrate lyase expression, and mTOR activity decreased, whereas AMPK was activated,2 validating the effect of mIndy deletion in vivo.3 We do not know whether the findings in mice, human hepatoma cell lines, and human liver samples translate into chronic, physiologically significant effects in patients with HCC. Presumably, however, IL‐6 contributes to HCC development together with a complex molecular network, including phospholipids, citrate, AMPK, and mTOR. This part of the argument by Chen et al., therefore, is pertinent and plausible. It is thus reassuring that small molecule inhibitors of mINDY are available,4 because they may serve as interesting tools for the study of mIndy and citrate in hepatic tumorigenesis. Moreover, according to the data discussed above, inhibition of mINDY may hold the potential to be effective in the treatment of HCC; however, this notion needs to be studied further. Thus far, pharmacological inhibition of mINDY has been shown to be effective in improving glucose tolerance and reducing liver fat in diet‐induced obese mice,4 effects that also protect against HCC.
Association between male circumcision and women's biomedical health outcomes: a systematic review
Authors: Jonathan M Grund, Tyler S Bryant, Inimfon Jackson, Kelly Curran, Naomi Bock, Carlos Toledo, Joanna Taliano, Sheng Zhou, Jorge Martin del Campo, Ling Yang, Apollo Kivumbi, Peizi Li, Sherri Pals, Stephanie M Davis
Journal: The Lancet Global Health (2017)

BackgroundMale circumcision reduces men's risk of acquiring HIV and some sexually transmitted infections from heterosexual exposure, and is essential for HIV prevention in sub-Saharan Africa. Studies have also investigated associations between male circumcision and risk of acquisition of HIV and sexually transmitted infections in women. We aimed to review all evidence on associations between male circumcision and women's health outcomes to benefit women's health programmes.MethodsIn this systematic review we searched for peer-reviewed and grey literature publications reporting associations between male circumcision and women's health outcomes up to April 11, 2016. All biomedical (not psychological or social) outcomes in all study types were included. Searches were not restricted by year of publication, or to sub-Saharan Africa. Publications without primary data and not in English were excluded. We extracted data and assessed evidence on each outcome as high, medium, or low consistency on the basis of agreement between publications; outcomes found in fewer than three publications were indeterminate consistency.Findings60 publications were included in our assessment. High-consistency evidence was found for five outcomes, with male circumcision protecting against cervical cancer, cervical dysplasia, herpes simplex virus type 2, chlamydia, and syphilis. Medium-consistency evidence was found for male circumcision protecting against human papillomavirus and low-risk human papillomavirus. Although the evidence shows a protective association with HIV, it was categorised as low consistency, because one trial showed an increased risk to female partners of HIV-infected men resuming sex early after male circumcision. Seven outcomes including HIV had low-consistency evidence and six were indeterminate.InterpretationScale-up of male circumcision in sub-Saharan Africa has public health implications for several outcomes in women. Evidence that female partners are at decreased risk of several diseases is highly consistent. Synergies between male circumcision and women's health programmes should be explored.FundingUS Centers for Disease Control and Prevention and Jhpiego.
A novel proteogenomics approach identifying key proteins in severe COPD
Authors: C.A. Brandsma, V. Guryev, W. Timens, D.S. Postma, R. Bischoff, M. Yakovleva, G. Marko-Varga, T. Fehniger, M. Van Den Berge, P. Horvatovich
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale COPD is influenced by many genetic and environmental factors. Genetic studies provided insights in the molecular mechanisms underlying COPD, but did not inform on protein changes. We propose that whichever factor contributes to disease, the final common pathway for disease development lies in the proteome. Therefore, we performed a combined proteome and RNA sequencing analysis comparing severe COPD and non-COPD control lung tissue. Methods Frozen lung tissue samples from 10 ex-smoking stage IV COPD patients and 10 ex-smoking non-COPD controls were used for protein and RNA extraction using urea and ammonium bicarbonate buffer and Trizol, respectively. The trypsin digested protein extract was analysed with LC-MS/MS approach using the Q-Exactive Plus (Thermo Scientific). RNA sequencing was performed with polyA-selected RNA sequencing using strand-specific quantitative NextFlex qRNA-Seq kit (Bio scientific) on Illumina HiSeq 2500 equipment with 20 million sequencing reads. We constructed patient specific protein reference databases using the RNA sequencing data and these were used to optimise peptide and protein identification. Differential gene and protein expression was assessed using linear models correcting for age, gender, age x gender interaction, and unwanted variation. FDR
Retrospective analysis of a SHIVA01 trial cohort using functional mutational analysis successfully predicted treatment outcome
Authors: G. Tarcic, C. Le Tourneau, M. Kamal, O. Edelheit, Z. Barbash, M. Vidne, S. Dureau, B. Miron, C. Callens, N. Servant, I. Bieche
Journal: Annals of Oncology (2017)
Clinical value of cfDNA and CTCs in EGFR mutations detected in advanced NSCLC
Authors: S. Calabuig Fariñas, E. Jantus-Lewintre, A. Fernández, C. Mayo de las Casas, A. Blasco, C. Aguilar, N. Jordana, A. Balada, M. Garzón Ibañez, F. Zhang, N. Dong, M.A. Molina, R. Rosell, C. Camps Herrero
Journal: Annals of Oncology (2017)
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity
Authors: Xiaoyan Wu, Zhenhua Hu, Sara Nizzero, Guodong Zhang, Maricela R. Ramirez, Ce Shi, Jin Zhou, Mauro Ferrari, Haifa Shen
Journal: Journal of Controlled Release (2017)
Hybrid-capture based genomic profiling identifies BRAF V600 and non-V600 alterations in melanoma samples negative by prior testing
Authors: L. Boussemart, A. Wang, M.K.K. Wong, J.S. Ross, P.J. Stephens, S.M. Ali, J. Sosman, J.M. Mehnert, G. Daniels, K. Kendra, A.B. Schrock, V.A. Miller
Journal: Annals of Oncology (2017)
Use of nivolumab in elderly patients with advanced non-squamous NSCLC: Results from the Italian expanded access program (EAP)
Authors: M.R. Migliorino, A. Gelibter, F. Grossi, D. Fagnani, P. Bordi, T. Franchina, D. Turci, L. Di Lauro, S. Cascinu, L. Calabro, M. Brighenti, N. Tedde, A. Bearz, S. Giusti, E. Vasile, G. Surico, G. Cartenì, P. Marchetti, F. Verderame, B. Melotti
Journal: Annals of Oncology (2017)
Phase 1 Study of IMAB362 with immunomodulation in patients with advanced gastric cancer
Authors: S-E. Al-Batran, Z. Zvirbule, F. Lordick, P. Thuss-Patience, M. Just, M. Bitzer, V. Brass, A. Krilova, D. Maurus, Ö. Türeci, U. Sahin
Journal: Annals of Oncology (2017)
Trajectories of Injectable Cancer Drug Costs After Launch in the United States
Authors: Noa Gordon, Salomon M. Stemmer, Dan Greenberg, Daniel A. Goldstein
Journal: Journal of Clinical Oncology (2017)

Purpose Cancer drug prices at launch have increased in recent years. It is unclear how individual drug prices change over time after launch and what market determinants influence these changes. We measured the price trajectories of a cohort of cancer drugs after their launch into the US market and assessed the influence of market structure on price changes. Methods We studied the changes in mean monthly costs for a cohort of 24 patented, injectable anticancer drugs that were approved by the US Food and Drug Administration between 1996 and 2012. To account for discounts and rebates, we used the average sales prices published by the Centers for Medicare and Medicaid Services. Costs were adjusted to US general and health-related inflation rates. For each drug, we calculated the cumulative and annual drug cost changes. We then used a multivariable regression model to evaluate the association between market and cost changes over time. Results With a mean follow-up period of 8 years, the mean percent change in cost for all drugs was +25% (range, -14% to +96%). After adjusting for inflation, the mean cost change was +18% (range, -16% to +59%). Rituximab and trastuzumab followed a similar pattern in cost increases over time, and the inflation-adjusted monthly costs rose since approval by 49% and 44%, respectively. New supplemental US Food and Drug Administration approvals, new off-label indications, and new competitors did not influence the annual cost change rates. Conclusion Anticancer drug costs may change substantially after launch. Regardless of competition or supplemental indications, there is a steady increase in costs of patented anticancer agents over time. New regulations may be needed to prevent additional increases in drug costs after launch.
GW28-e0651 Association between homocysteine levels and calcific aortic valve disease: a meta-analysis
Authors: Qingchun Zeng, Guandi Wu, Jiayi Xian, Jun Li, Die Zhu, Ruxia Liang, Xi Yang, Jiaying Li, Ying Huang, Yan Tu, Dingli Xu
Journal: Journal of the American College of Cardiology (2017)